Lanzaar

Losartan K

HTN. Diabetic nephropathy in patients w/ type 2 DM (NIDDM) & history of HTN. Stroke risk reduction in patients w/ HTN & left ventricular hypertrophy (LVH).

HTN Adult Initially 50 mg once daily. Total dose range: 25-100 mg once or bid. Childn 6-16 yr 0.7 mg/kg once daily. Max: 50 mg daily. Patients receiving diuretics or w/ intravascular vol depletion Initially 25 mg. Nephropathy in patients w/ type 2 DM & HTN Adult Initially 50 mg once daily, may be increased to 100 mg once daily based on BP response. Stroke reduction (HTN w/ LVH) Adult 50 mg once daily up to max daily dose: 100 mg in combination w/ thiazide diuretic. Hepatic impairment Initially 25 mg daily in 2 divided doses.

May be taken with or without food.

Hypersensitivity to losartan & other angiotensin II receptor antagonists. Concomitant use w/ aliskiren (renin inhibitor) in patients w/ DM. Pregnancy.

Discontinue if angioedema of face, tongue, glottis, or difficulty in breathing occurs. Patients w/ pre-existing renal insufficiency or significant aortic/mitral stenosis; unilateral or bilateral renal artery stenosis. Not to be used in patients receiving K or K-sparing diuretics. Avoid use in vol-depleted patients. Depression, nausea, vomiting. African-American patients w/ HTN & LVH. Renal failure; CrCl <30 mL/min. Hemodialysis patients. Hepatic dysfunction. Not to be used in pregnancy. Not recommended during lactation. Not recommended in childn w/ GFR <30 mL/min/1.73 m².

Chest pain; fatigue; hypoglycemia; diarrhea; UTI; anemia; weakness, back pain; cough. Hypotension, orthostatic & 1st-dose hypotension; dizziness, hypoesthesia, fever, insomnia; cellulitis; hyperkalemia; gastritis, wt gain, abdominal pain, nausea; muscular weakness, knee & leg pain, muscle cramps, myalgia; bronchitis, URTI, nasal congestion, sinusitis; infection, flu-like syndrome.

Metabolism/transport effects w/ major CYP2C9 & CYP3A4 substrates. Inhibited metabolism/transport effects of weak CYP1A2, CYP2C19, CYP3A4 & moderate CYP2C8, CYP2C9 enzymes. Concomitant use w/ pimozide. Increased levels/effects of ACE inhibitors, amifostine, antihypertensives, aripiprazole, carvedilol, systemic cyclosporine, CYP2C8 & CYP2C9 substrates, hypoglycemics, hypotensives, lithium, lomitapide, NSAIDs, pimozide, K-sparing diuretics, rituximab, Na phosphates. Increased levels/effects by alfuzosin, aliskiren, azole derivative & systemic antifungals, moderate & strong CYP2C9 inhibitors, diazoxide, eplerenone, fluconazole, herbs w/ hypoglycemic & hypotensive properties, MAOIs, mifepristone, milk thistle, pentoxifylline, phosphodiesterase-5 inhibitors, K salts, prostacyclin analogues, salicylates, SSRIs, tolvaptan, trimethoprim. Decreased levels/effects by strong CYP2C9 & CYP3A4 inducers, herbs w/ hypertensive properties, loop diuretics, methylphenidate, NSAIDs, peginterferon α-2b, rifamycin derivatives, tocilizumab, yohimbine.

Angiotensin II Antagonists

C09CA01 - losartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

D